EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method Report of the Zyvox Antimicrobial Potency Study in the United States



Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method Report of the Zyvox Antimicrobial Potency Study in the United States



Diagnostic Microbiology & Infectious Disease 40(1-2): 59-66, May-June



The in vitro activity of linezolid against common Gram-positive pathogens was compared to that of penicillin or ampicillin or oxacillin (depending upon genus), cefazolin, erythromycin, clindamycin, quinupristin/dalfopristin, levofloxacin, nitrofurantoin and vancomycin by disk diffusion methods. One hundred and six centers (31 states in US) tested recent clinical isolates of Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecium, E. faecalis, Streptococcus pneumoniae, and other streptococci. Testing was conducted using the standardized disk diffusion method and concurrent quality control testing was performed. Strains with linezolid zone diameters of ltoreq20 mm were requested for referral to the microbiology monitor for confirmation. A total of 3,100 isolates (97% compliance) were tested. Susceptibility (zone diameters, gtoreq21 mm) of staphylococci and streptococci to linezolid was reported in 100% and 99.4% of staphylococci and streptococci, respectively. Susceptibility (zone diameters, gtoreq23 mm) of enterococci to linezolid was 96.0% with only three isolates (0.4%) reported as resistant (zone diameters, ltoreq20 mm; unconfirmed). Among a total of nine isolates (0.3%) reported to have zone diameters 20 mm, six were not submitted for further testing, two were contaminated with Gram-negative bacilli and one was determined to be linezolid-susceptible. There were no differences in linezolid susceptibility in the vancomycin- or oxacillin- or penicillin-resistant subsets of strains. This susceptibility pattern for US medical centers is indicative of the excellent and nearly complete in vitro activity against the key Gram-positive pathogens for which linezolid has received US Food and Drug Administration indications for clinical use.

(PDF 0-2 workdays service: $29.90)

Accession: 035349270

Download citation: RISBibTeXText



Related references

Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States. Diagnostic Microbiology and Infectious Disease 40(1-2): 59-66, 2001

Multi-center assessment of linezolid spectrum and potency in the United States using the standardized disk diffusion method Report from the zyvox antimicrobial potency study. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 193, 2001

Multicenter assessment of the linezolid spectrum and activity using the disk diffusion and Etest methods: report of the Zyvox(R) antimicrobial potency study in Latin America (LA-ZAPS). Brazilian Journal of Infectious Diseases 6(3): 100-109, 2002

Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvox antimicrobial potency study (ZAPS-Europe). Clinical Microbiology and Infection 8(12): 791-800, 2003

Five-year longitudinal assessment of linezolid (LZD) activity in Europe(EU): Results from the Zyvox (R) Annual Appraisal of Potency and Spectrum (ZAAPS). 2007

Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) program: report of linezolid activity over 9 years (2004-12). Journal of Antimicrobial ChemoTherapy 69(6): 1582-1588, 2015

Study on drug sensitivity against Comamonas testosteroni by Kirby-Bauer disk diffusion method. Zhong Nan Da Xue Xue Bao. Yi Xue Ban 41(8): 856-859, 2016

Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries. Diagnostic Microbiology and Infectious Disease 59(2): 199-209, 2007

PNU-288034 In vitro potency compared to linezolid, spectrum of antimicrobial activity, and confirmation of disk mass. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 42: 216-217, 2002

Incidence of antimicrobial resistance and comparison of a commercially available improved medium for antimicrobial susceptibility testing of haemophilus influenzae with the nccls reference kirby bauer disk diffusion technique. Abstracts of the Annual Meeting of the American Society for Microbiology 89: 404, 1989

An automated antimicrobial susceptibility system versus the Kirby-Bauer disk diffusion test for antimicrobial susceptibility. American Journal of Clinical Pathology 71(1): 131-133, 1979

Update on linezolid in vitro activity through the Zyvox Annual Appraisal of Potency and Spectrum Program, 2013. Antimicrobial Agents and ChemoTherapy 59(4): 2454-2457, 2015

Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program. Diagnostic Microbiology and Infectious Disease 52(1): 53-58, 2005